Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Scholar Rock Holding Corp
(NQ:
SRRK
)
38.15
+1.09 (+2.94%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Scholar Rock Holding Corp
< Previous
1
2
3
4
5
6
7
8
9
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 25, 2024
Via
Benzinga
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
November 25, 2024
Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24.
Via
Benzinga
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
November 25, 2024
Via
Benzinga
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2024
From
Scholar Rock
Via
Business Wire
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
October 25, 2024
Via
Benzinga
How Is The Market Feeling About Scholar Rock Holding?
October 07, 2024
Via
Benzinga
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
November 12, 2024
From
Scholar Rock
Via
Business Wire
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
November 04, 2024
From
Scholar Rock, Inc.
Via
Business Wire
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
November 01, 2024
From
Scholar Rock
Via
Business Wire
Scholar Rock to Participate in Upcoming Investor Conferences
October 31, 2024
From
Scholar Rock
Via
Business Wire
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
October 31, 2024
From
Scholar Rock
Via
Business Wire
Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering
October 22, 2024
From
Scholar Rock
Via
Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2024
From
Scholar Rock
Via
Business Wire
Here's Why Everybody's Talking About Scholar Rock Right Now
October 09, 2024
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.
Via
The Motley Fool
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants
October 08, 2024
From
Scholar Rock
Via
Business Wire
Nasdaq To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday
October 08, 2024
Via
Benzinga
Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
October 07, 2024
From
Scholar Rock
Via
Business Wire
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
October 07, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
October 07, 2024
Via
Benzinga
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
October 07, 2024
Via
Benzinga
Exposures
Fossil Fuels
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
October 07, 2024
Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared...
Via
Benzinga
Exposures
Product Safety
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
October 07, 2024
Via
Benzinga
US Stocks Open Lower; Dow Tumbles Over 150 Points
October 07, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy
October 07, 2024
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 07, 2024
Via
Benzinga
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)
October 07, 2024
From
Scholar Rock
Via
Business Wire
Constellation Energy, Nike, Sinclair And Other Big Stocks Moving Higher On Friday
September 20, 2024
Via
Benzinga
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 13, 2024
From
Scholar Rock
Via
Business Wire
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
September 10, 2024
From
Scholar Rock
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.